Azura Ophthalmics - Taking a unique approach to the treatment of ocular surface disease
Employees: 11-50
Total raised: $40M
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | OrbiMed | orbimed.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.10.2020 | - | $20M | - |
| 10.10.2017 | Series B | $20M | - |
Mentions in press and media 7
| Date | Title | Description | Source |
| 02.04.2024 | Azura Ophthalmics to Present New Data Supporting the Potenti... | —Azura to present 10 abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) an... | brandoncap... |
| 07.09.2021 | Azura Ophthalmics Appoints Biopharma Industry Veteran Steven... | Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian Gland... | brandoncap... |
| 26.10.2020 | Azura Ophthalmics Raises US$20M in Funding | Azura Ophthalmics Ltd., a Tel Aviv, Israel-based clinical-stage company developing innovative therap... | finsmes.co... |
| 23.10.2020 | Azura Ophthalmics raises AUD$28m for registration studies fo... | Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland... | brandoncap... |
| 19.10.2017 | Biotech startup Azura Ophthalmics raises $20 million to cure... | Azura Ophthalmics chief Marc Gleeson. Source: Supplied. Australian and Israeli-based biotech startup... | smartcompa... |
| 10.10.2017 | Azura Ophthalmics Receives $16M in Series B Funding | Azura Ophthalmics Ltd., a Tel Aviv-Yafo, Israel-based clinical-stage biotechnology company developin... | finsmes.co... |
| 10.10.2017 | OrbiMed Leads $16M Series B for Azura Ophthalmics | TEL AVIV, Israel--(BUSINESS WIRE)--Azura Ophthalmics Ltd. (Azura), a clinical-stage biotechnology co... | citybizlis... |